XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2023
Summary of Disaggregation of Revenues

The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):

 

 

 

Three Months Ended

 

 

Three Months Ended

 

 

September 30, 2023

 

 

September 30, 2022

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

Product revenue, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEPLISAV-B

 

$

62,318

 

 

$

-

 

 

$

62,318

 

 

$

37,508

 

 

$

-

 

 

$

37,508

 

CpG 1018 adjuvant

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

126,307

 

 

 

126,307

 

Total product revenue, net

 

$

62,318

 

 

$

-

 

 

$

62,318

 

 

$

37,508

 

 

$

126,307

 

 

$

163,815

 

Other revenue

 

 

7,196

 

 

 

-

 

 

 

7,196

 

 

 

3,877

 

 

 

43

 

 

 

3,920

 

Total revenues

 

$

69,514

 

 

$

-

 

 

$

69,514

 

 

$

41,385

 

 

$

126,350

 

 

$

167,735

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

Nine Months Ended

 

 

September 30, 2023

 

 

September 30, 2022

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

 

U.S.

 

 

Non U.S.

 

 

Total

 

Product revenue, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEPLISAV-B

 

$

162,209

 

 

$

-

 

 

$

162,209

 

 

$

90,057

 

 

$

941

 

 

$

90,998

 

CpG 1018 adjuvant

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

440,464

 

 

 

440,464

 

Total product revenue, net

 

$

162,209

 

 

$

-

 

 

$

162,209

 

 

$

90,057

 

 

$

441,405

 

 

$

531,462

 

Other revenue

 

 

14,479

 

 

 

-

 

 

 

14,479

 

 

 

6,566

 

 

 

163

 

 

 

6,729

 

Total revenues

 

$

176,688

 

 

$

-

 

 

$

176,688

 

 

$

96,623

 

 

$

441,568

 

 

$

538,191

 

 

HEPLISAV-B  
Schedule of Revenues from Major Customers

The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Largest customer

 

 

27

%

 

 

23

%

 

 

25

%

 

 

20

%

Second largest customer

 

 

25

%

 

 

19

%

 

 

24

%

 

 

18

%

Third largest customer

 

 

18

%

 

 

18

%

 

 

17

%

 

 

17

%

Summary of Product Revenue Allowance and Reserve Categories

The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the nine months ended September 30, 2023 (in thousands):

 

 

 

Balance at
Beginning
of Period

 

 

Provisions
related to
current
period sales

 

 

Credit or
payments
made during
the period

 

 

Adjustments related to prior periods

 

 

Balance
at End of
Period

 

Nine months ended September 30, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves (1)

 

$

8,179

 

 

$

42,949

 

 

$

(40,186

)

 

$

(2,629

)

 

$

8,313

 

Revenue reserve accruals (2)

 

$

10,552

 

 

$

34,848

 

 

$

(27,528

)

 

$

2,297

 

 

$

20,169

 

 

(1)
Reserves are for chargebacks, discounts and other fees.
(2)
Accruals are for returns, rebates and other fees.
CpG 1018  
Schedule of Revenues from Major Customers

The following table summarizes CpG 1018 adjuvant product revenue from each of our three largest collaboration partners (as a percentage of total CpG 1018 adjuvant net product revenue):

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Largest collaboration partner

 

 

0

%

 

 

69

%

 

 

0

%

 

 

46

%

Second largest collaboration partner

 

 

0

%

 

 

22

%

 

 

0

%

 

 

33

%

Third largest collaboration partner

 

 

0

%

 

 

9

%

 

 

0

%

 

 

15

%

Summarizes balances and activities in our contract asset account The following table summarizes balances and activities in our contract asset account (in thousands):

 

 

 

Balance at
Beginning
of Period

 

 

Additions

 

 

Subtractions

 

 

Reclassification (1)

 

 

Balance
at End of
Period

 

Nine months ended September 30, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contract asset, included in other current assets (2)

 

$

71,965

 

 

$

14,396

 

 

$

(13,175

)

 

$

(71,307

)

 

$

1,879

 

Contract asset, included in other assets (long term)

 

$

-

 

 

$

-

 

 

$

-

 

 

$

71,307

 

 

$

71,307

 

 

 

(1)
The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 6 for further discussion.
(2)
The $1.9 million of contract asset is derived from our agreement with the DoD.